Business Wire

ETSI releases first O-RAN specification

Share

ETSI and O-RAN are pleased to announce that ETSI has adopted the first O-RAN specification as ETSI TS 103 859, namely ‘O-RAN Fronthaul Control, User and Synchronization Plane Specification v7.02’. The document focuses on Open Fronthaul, one of interfaces in the O-RAN Architecture for open and intelligent Radio Access Networks. It specifies the control plane, user plane and synchronization plane protocols used over the fronthaul interface linking the O-DU (O-RAN Distributed Unit) and the O-RU (O-RAN Radio Unit) for the lower layer functional splits. The scope of TS 103 859 includes both LTE and NR (5G).

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220915005642/en/

“Recognition of O-RAN specifications by ETSI is another major step in enabling broad adoption of Open RAN,” said Claire Chauvin, O-RAN Board member and Strategy Architecture and Standardization Director at Orange. “Having the O-RAN specification available as an ETSI specification adds further endorsement desired by commercial and public sector entities in a range of countries.”

“The O-RAN specification has been approved as an ETSI specification after a thorough review and requested revisions by our experts,” said Dominique Everaere, Chair of the ETSI Mobile Standards Group Technical Committee. “When specifications go through the ETSI PAS process, they need to comply with the ETSI rules, and the ETSI committee in charge of these specifications works with the organization to ensure they align with existing procedures for approval as ETSI standards.”

The ETSI Publicly Available Specification (PAS) process enables an ETSI partner to submit one or more of its PAS for adoption by ETSI. It can then become an ETSI Technical Specification (TS) or ETSI Technical Report (TR). The organization asking for this process must be a legal entity, have an IPR policy compatible with ETSI’s or have exceptionally accepted to apply ETSI’s IPR policy, and have signed a Cooperation Agreement.

O-RAN is preparing to submit more of its specifications to the ETSI PAS process to recognize additional parts of the O-RAN Architecture as ETSI specifications.

About ETSI

ETSI provides members with an open and inclusive environment to support the development, ratification and testing of globally applicable standards for ICT systems and services across all sectors of industry and society. We are a non-profit body, with more than 900 member organizations worldwide, drawn from 64 countries and five continents. The members comprise a diversified pool of large and small private companies, research entities, academia, government, and public organizations. ETSI is officially recognized by the EU as a European Standardization Organization (ESO). For more information, please visit us at https://www.etsi.org/.

About O-RAN ALLIANCE

The O-RAN ALLIANCE is a world-wide community of more than 320 mobile operators, vendors, and research & academic institutions operating in the Radio Access Network (RAN) industry. As the RAN is an essential part of any mobile network, the O-RAN ALLIANCE’s mission is to re-shape the industry towards more intelligent, open, virtualized and fully interoperable mobile networks. The new O-RAN specifications enable a more competitive and vibrant RAN supplier ecosystem with faster innovation to improve user experience. O-RAN based mobile networks at the same time improve the efficiency of RAN deployments as well as operations by the mobile operators. To achieve this, the O-RAN ALLIANCE publishes new RAN specifications, releases open software for the RAN, and supports its members in integration and testing of their implementations.

For more information, please visit www.o-ran.org.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

ETSI Press contact:
Claire Boyer
Tel.: +33 (0)6 87 60 84 40
Email: claire.boyer@etsi.org

O-RAN ALLIANCE PR Contact:
Zbynek Dalecky
pr@o-ran.org
O-RAN ALLIANCE e.V.
Buschkauler Weg 27
53347 Alfter/Germany

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Kinaxis Positioned Highest on Ability to Execute in the Gartner® Magic Quadrant™ for Supply Chain Planning Solutions26.4.2024 18:03:00 CEST | Press release

Kinaxis® Inc. (TSX:KXS), a global leader in end-to-end supply chain orchestration, today announced it has been named a Leader in the 2024 Gartner® Magic Quadrant™ for Supply Chain Planning Solutions. Of the 20 vendors evaluated, Gartner positioned Kinaxis highest on Ability to Execute, marking the company’s 10th consecutive Leaders Quadrant within the report, a complimentary copy of which can be downloaded here. Kinaxis attributes its position to its patented concurrency approach and a proven track record of delivering innovative solutions against the foundation of its leading vision through the use of advanced technology such as AI, ML, and an intuitive user experience. Bolstered by a rich ecosystem of third-party implementation partners, Kinaxis continues to demonstrate that regardless of a customer’s industry, size, or maturity level, the company can be counted on to seamlessly orchestrate supply chain networks end-to-end from strategic planning to last-mile delivery. The recognitio

Vertex Announces European Commission Approval for KALYDECO ® to Treat Infants With Cystic Fibrosis Ages 1 Month and Older26.4.2024 17:43:00 CEST | Press release

Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Commission has granted approval for the label expansion of KALYDECO® (ivacaftor) for the treatment of infants down to 1 month of age with cystic fibrosis (CF) who have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene: R117H, G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R. “Today’s approval is an important milestone for the cystic fibrosis community. Treating CF early in life can potentially slow the progression of the disease, which is why it is so important to start treatment from a very young age,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer, Vertex. As a result of existing access agreements in Austria, Czech Republic, Denmark, Ireland, Norway, Sweden, and The Netherlands, eligible patients will have access to the expanded indication of KALYDECO® (ivacaftor)

Suzano 2023 annual report on Form 20-F26.4.2024 17:22:00 CEST | Press release

Suzano S.A. (B3: SUZB3 | NYSE: SUZ) informs that its 2023 Annual Report on Form 20-F was filed today with the U.S. Securities and Exchange Commission. Holders of the Company’s equity securities can receive hard copies of the Annual Report, including its audited financial statements, without charge by request directed to: ri@suzano.com.br. This document is also available on Suzano’s website (http://ir.suzano.com.br/). For further information, please contact our Investor Relations Department: Phone: (+55 11) 3503-9330 E-mail: ri@suzano.com.br View source version on businesswire.com: https://www.businesswire.com/news/home/20240426289818/en/Contact information Hawthorn Advisors suzano@hawthornadvisors.com

Takeda Receives Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer26.4.2024 14:30:00 CEST | Press release

Takeda (TSE:4502/NYSE:TAK) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of fruquintinib, a selective inhibitor of vascular endothelial growth factor receptors (VEGFR) -1, -2 and -3 for the treatment of adult patients with previously treated metastatic colorectal cancer (mCRC). The European Commission (EC) will consider the CHMP positive opinion when determining the potential marketing authorization for fruquintinib for mCRC throughout the European Union (EU), Norway, Liechtenstein and Iceland. If approved, fruquintinib will be the first and only selective inhibitor of all three VEGF receptors approved in the EU for previously treated mCRC.1,2 “People living with metastatic colorectal cancer in the European Union currently have limited treatment options, which can lead to poor outcomes. With this positive opinion for fruquintinib, we are one step closer to potentially offering patients a new

MEDIA ALERT: Wolters Kluwer expert comments on European Parliament vote to pass amendment implementing Basel III reforms26.4.2024 14:00:00 CEST | Press release

The European financial landscape saw a milestone event this week, as the EU Parliament passed the Amendment to Regulation (EU) No 575/2013, implementing the Basel III finalization within Europe. This monumental step forward comes with the adoption of the Capital Requirements Regulation (CRR3) amendments, which are part of a broader legislative package, including amendments to Directive 2013/36/EU, known as the Capital Requirements Directive or CRD. Jeroen Van Doorsselaere, Vice President of Global Product & Platform Management, Wolters Kluwer FRR, said: “The adoption of the Capital Requirements Regulation (CRR3) amendments represents a landmark change for the banking industry, designed to strengthen the framework for risk-based capital requirements and address ESG risks. “This is a major overhaul of the capital requirements framework, impacting various aspects, including credit risk, operational risk, market risk, and the capital floor. Whereas other significant jurisdictions, includin

HiddenA line styled icon from Orion Icon Library.Eye